Article Versions Notes

Seban R-D, Assié J-B, Giroux-Leprieur E, Massiani M-A, Soussan M, Bonardel G, Chouaid C, Playe M, Goldfarb L, Duchemann B, et al. Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers. 2020; 12(8):2234. https://doi.org/10.3390/cancers12082234

Seban, Romain-David, Jean-Baptiste Assié, Etienne Giroux-Leprieur, Marie-Ange Massiani, Michael Soussan, Gérald Bonardel, Christos Chouaid, Margot Playe, Lucas Goldfarb, Boris Duchemann, and et al. 2020. "Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab" Cancers 12, no. 8: 2234. https://doi.org/10.3390/cancers12082234

Seban, R. -D., Assié, J. -B., Giroux-Leprieur, E., Massiani, M. -A., Soussan, M., Bonardel, G., Chouaid, C., Playe, M., Goldfarb, L., Duchemann, B., Mezquita, L., Girard, N., & Champion, L. (2020). Association of the Metabolic Score Using Baseline FDG-PET/CT and dNLR with Immunotherapy Outcomes in Advanced NSCLC Patients Treated with First-Line Pembrolizumab. Cancers, 12(8), 2234. https://doi.org/10.3390/cancers12082234